Viral Signaling and Targeting Strategies
Kieser GroupThe viral signaling and targeting strategies group investigates the molecular basis of cell transformation by the latent membrane protein 1 (LMP1), the primary oncogene of the human Epstein-Barr tumor virus (EBV). Using state-of-the-art technologies such as proteomics, we focus at elucidating the molecular interactions of LMP1 with the cellular signaling network to define LMP1’s contribution to chronic disease development by EBV infection. The aim is to identify and validate novel targets and to develop targeting strategies such as small molecule inhibitors to interfere with LMP1 signaling and lymphomagenesis by EBV. The relevance of such new targets for other diseases are also investigated.
The viral signaling and targeting strategies group investigates the molecular basis of cell transformation by the latent membrane protein 1 (LMP1), the primary oncogene of the human Epstein-Barr tumor virus (EBV). Using state-of-the-art technologies such as proteomics, we focus at elucidating the molecular interactions of LMP1 with the cellular signaling network to define LMP1’s contribution to chronic disease development by EBV infection. The aim is to identify and validate novel targets and to develop targeting strategies such as small molecule inhibitors to interfere with LMP1 signaling and lymphomagenesis by EBV. The relevance of such new targets for other diseases are also investigated.
Our Scientists
Our Publications
Weiterlesen2024 Wissenschaftlicher Artikel in Nature Communications
Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex.
2023 Wissenschaftlicher Artikel in Frontiers in Cardiovascular Medicine
Deficiency of germinal center kinase TRAF2 and NCK-interacting kinase (TNIK) in B cells does not affect atherosclerosis.
